Carbapenemase-Producing Enterobacteriaceae

 

 Permissions and Reprints

Abstract

Carbapenemase-producing Enterobacteriaceae (CPE) were almost nonexistent up to the 1990s, but are today encountered routinely in hospitals and other healthcare facilities in many countries including the United States. KPC-producing Klebsiella pneumoniae was the first to emerge and spread globally and is endemic in the United States, Israel, Greece, and Italy. Recently, NDM-producing Enterobacteriaceae and OXA-48-producing K. pneumoniae appear to be disseminating from South Asia and Northern Africa, respectively. They are almost always resistant to all β-lactams including carbapenems and many other classes. Mortality from invasive CPE infections reaches up to 40%. To obtain the maximal benefit from the limited options available, dosing of antimicrobial agents should be optimized based on pharmacokinetic data, especially for colistin and carbapenems. In addition, multiple observational studies have associated combination antimicrobial therapy with lower mortality compared with monotherapy for these infections. The outcomes appear to be especially favorable when patients are treated with a carbapenem and a second agent such as colistin, tigecycline, and gentamicin, but the best approach is yet to be defined.

• References

• 1 Rasmussen BA, Bush K. Carbapenem-hydrolyzing β-lactamases. Antimicrob Agents Chemother 1997; 41 (2) 223-232
  PubMedGoogle Scholar
• 2 Martínez-Martínez L, Pascual A, Hernández-Allés S , et al. Roles of β-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae . Antimicrob Agents Chemother 1999; 43 (7) 1669-1673
  PubMedGoogle Scholar
• 3 Yigit H, Queenan AM, Anderson GJ , et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae . Antimicrob Agents Chemother 2001; 45 (4) 1151-1161
  CrossrefPubMedGoogle Scholar
• 4 Bradford PA, Bratu S, Urban C , et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin Infect Dis 2004; 39 (1) 55-60
  CrossrefPubMedGoogle Scholar
• 5 Bratu S, Landman D, Haag R , et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005; 165 (12) 1430-1435
  CrossrefPubMedGoogle Scholar
• 6 Kitchel B, Rasheed JK, Patel JB , et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009; 53 (8) 3365-3370
  CrossrefPubMedGoogle Scholar
• 7 Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011; 53 (1) 60-67
  CrossrefPubMedGoogle Scholar
• 8 Samra Z, Ofir O, Lishtzinsky Y, Madar-Shapiro L, Bishara J. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int J Antimicrob Agents 2007; 30 (6) 525-529
  CrossrefPubMedGoogle Scholar
• 9 Navon-Venezia S, Leavitt A, Schwaber MJ , et al; Israeli KPC Kpn Study Group. First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother 2009; 53 (2) 818-820
  CrossrefPubMedGoogle Scholar
• 10 Schwaber MJ, Lev B, Israeli A , et al; Israel Carbapenem-Resistant Enterobacteriaceae Working Group. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011; 52 (7) 848-855
  CrossrefPubMedGoogle Scholar
• 11 Schwaber MJ, Carmeli Y. An ongoing national intervention to contain the spread of carbapenem-resistant enterobacteriaceae. Clin Infect Dis 2014; 58 (5) 697-703
  CrossrefPubMedGoogle Scholar
• 12 Maltezou HC, Giakkoupi P, Maragos A , et al. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J Infect 2009; 58 (3) 213-219
  CrossrefPubMedGoogle Scholar
• 13 Psichogiou M, Tassios PT, Avlamis A , et al. Ongoing epidemic of bla _VIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. J Antimicrob Chemother 2008; 61 (1) 59-63
  PubMedGoogle Scholar
• 14 Agodi A, Voulgari E, Barchitta M , et al. Containment of an outbreak of KPC-3-producing Klebsiella pneumoniae in Italy. J Clin Microbiol 2011; 49 (11) 3986-3989
  CrossrefPubMedGoogle Scholar
• 15 Giani T, Pini B, Arena F , et al. Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey, 15 May to 30 June 2011. Euro Surveill 2013; 18 (22)
  PubMedGoogle Scholar
• 16 Munoz-Price LS, Poirel L, Bonomo RA , et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13 (9) 785-796
  CrossrefPubMedGoogle Scholar
• 17 Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 2011; 35 (5) 736-755
  CrossrefPubMedGoogle Scholar
• 18 Warburg G, Hidalgo-Grass C, Partridge SR , et al. A carbapenem-resistant Klebsiella pneumoniae epidemic clone in Jerusalem: sequence type 512 carrying a plasmid encoding aac(6′)-Ib . J Antimicrob Chemother 2012; 67 (4) 898-901
  CrossrefPubMedGoogle Scholar
• 19 Capone A, Giannella M, Fortini D , et al; SEERBIO-GRAB network. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013; 19 (1) E23-E30
  CrossrefPubMedGoogle Scholar
• 20 Qi Y, Wei Z, Ji S, Du X, Shen P, Yu Y. ST11, the dominant clone of KPC-producing Klebsiella pneumoniae in China. J Antimicrob Chemother 2011; 66 (2) 307-312
  CrossrefPubMedGoogle Scholar
• 21 Pereira PS, de Araujo CF, Seki LM, Zahner V, Carvalho-Assef AP, Asensi MD. Update of the molecular epidemiology of KPC-2-producing Klebsiella pneumoniae in Brazil: spread of clonal complex 11 (ST11, ST437 and ST340). J Antimicrob Chemother 2013; 68 (2) 312-316
  CrossrefPubMedGoogle Scholar
• 22 Ruiz-Garbajosa P, Curiao T, Tato M , et al. Multiclonal dispersal of KPC genes following the emergence of non-ST258 KPC-producing Klebsiella pneumoniae clones in Madrid, Spain. J Antimicrob Chemother 2013; 68 (11) 2487-2492
  CrossrefPubMedGoogle Scholar
• 23 O'Hara JA, Hu F, Ahn C , et al. Molecular epidemiology of KPC-producing Escherichia coli: occurrence of ST131-fimH30 subclone harboring pKpQIL-like IncFIIk plasmid. Antimicrob Agents Chemother 2014; 58 (7) 4234-4237
  CrossrefPubMedGoogle Scholar
• 24 Ahn C, Syed A, Hu F, O'Hara JA, Rivera JI, Doi Y. Microbiological features of KPC-producing Enterobacter isolates identified in a U.S. hospital system. Diagn Microbiol Infect Dis 2014; 80 (2) 154-158
  CrossrefPubMedGoogle Scholar
• 25 Robledo IE, Aquino EE, Vázquez GJ. Detection of the KPC gene in Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii during a PCR-based nosocomial surveillance study in Puerto Rico. Antimicrob Agents Chemother 2011; 55 (6) 2968-2970
  CrossrefPubMedGoogle Scholar
• 26 Yong D, Toleman MA, Giske CG , et al. Characterization of a new metallo-β-lactamase gene, bla _NDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53 (12) 5046-5054
  CrossrefPubMedGoogle Scholar
• 27 Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE. Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. Antimicrob Agents Chemother 2011; 55 (3) 1274-1278
  CrossrefPubMedGoogle Scholar
• 28 Castanheira M, Deshpande LM, Farrell SE, Shetye S, Shah N, Jones RN. Update on the prevalence and genetic characterization of NDM-1-producing Enterobacteriaceae in Indian hospitals during 2010. Diagn Microbiol Infect Dis 2013; 75 (2) 210-213
  CrossrefPubMedGoogle Scholar
• 29 Day KM, Ali S, Mirza IA , et al. Prevalence and molecular characterization of Enterobacteriaceae producing NDM-1 carbapenemase at a military hospital in Pakistan and evaluation of two chromogenic media. Diagn Microbiol Infect Dis 2013; 75 (2) 187-191
  CrossrefPubMedGoogle Scholar
• 30 Zowawi HM, Balkhy HH, Walsh TR, Paterson DL. β-Lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula. Clin Microbiol Rev 2013; 26 (3) 361-380
  CrossrefPubMedGoogle Scholar
• 31 Meletis G, Oustas E, Bagkeri M. Carbapenemase reports from the Balkans: a systematic review. Infez Med 2014; 22 (2) 85-106
  PubMedGoogle Scholar
• 32 Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011; 11 (5) 355-362
  CrossrefPubMedGoogle Scholar
• 33 Savard P, Gopinath R, Zhu W , et al. First NDM-positive Salmonella sp. strain identified in the United States. Antimicrob Agents Chemother 2011; 55 (12) 5957-5958
  CrossrefPubMedGoogle Scholar
• 34 Darley E, Weeks J, Jones L , et al. NDM-1 polymicrobial infections including Vibrio cholerae . Lancet 2012; 380 (9850) 1358
  CrossrefPubMedGoogle Scholar
• 35 Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae . Antimicrob Agents Chemother 2004; 48 (1) 15-22
  CrossrefPubMedGoogle Scholar
• 36 Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 2012; 67 (7) 1597-1606
  CrossrefPubMedGoogle Scholar
• 37 Mathers AJ, Hazen KC, Carroll J , et al. First clinical cases of OXA-48-producing carbapenem-resistant Klebsiella pneumoniae in the United States: the “menace” arrives in the new world. J Clin Microbiol 2013; 51 (2) 680-683
  CrossrefPubMedGoogle Scholar
• 38 Thaden JT, Lewis SS, Hazen KC , et al. Rising rates of carbapenem-resistant enterobacteriaceae in community hospitals: a mixed-methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States. Infect Control Hosp Epidemiol 2014; 35 (8) 978-983
  CrossrefPubMedGoogle Scholar
• 39 Nordmann P, Gniadkowski M, Giske CG, Poirel L, Woodford N, Miriagou V ; European Network on Carbapenemases. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2012; 18 (5) 432-438
  CrossrefPubMedGoogle Scholar
• 40 Anderson KF, Lonsway DR, Rasheed JK , et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae . J Clin Microbiol 2007; 45 (8) 2723-2725
  CrossrefPubMedGoogle Scholar
• 41 Nordmann P, Poirel L, Dortet L. Rapid detection of carbapenemase-producing Enterobacteriaceae . Emerg Infect Dis 2012; 18 (9) 1503-1507
  CrossrefPubMedGoogle Scholar
• 42 Vasoo S, Cunningham SA, Kohner PC , et al. Comparison of a novel, rapid chromogenic biochemical assay, the Carba NP test, with the modified Hodge test for detection of carbapenemase-producing Gram-negative bacilli. J Clin Microbiol 2013; 51 (9) 3097-3101
  CrossrefPubMedGoogle Scholar
• 43 Doi Y, Potoski BA, Adams-Haduch JM, Sidjabat HE, Pasculle AW, Paterson DL. Simple disk-based method for detection of Klebsiella pneumoniae carbapenemase-type β-lactamase by use of a boronic acid compound. J Clin Microbiol 2008; 46 (12) 4083-4086
  CrossrefPubMedGoogle Scholar
• 44 Tsakris A, Themeli-Digalaki K, Poulou A , et al. Comparative evaluation of combined-disk tests using different boronic acid compounds for detection of Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae clinical isolates. J Clin Microbiol 2011; 49 (8) 2804-2809
  CrossrefPubMedGoogle Scholar
• 45 Hattori T, Kawamura K, Arakawa Y. Comparison of test methods for detecting metallo-β-lactamase-producing Gram-negative bacteria. Jpn J Infect Dis 2013; 66 (6) 512-518
  CrossrefPubMedGoogle Scholar
• 46 Cuzon G, Naas T, Bogaerts P, Glupczynski Y, Nordmann P. Evaluation of a DNA microarray for the rapid detection of extended-spectrum β-lactamases (TEM, SHV and CTX-M), plasmid-mediated cephalosporinases (CMY-2-like, DHA, FOX, ACC-1, ACT/MIR and CMY-1-like/MOX) and carbapenemases (KPC, OXA-48, VIM, IMP and NDM). J Antimicrob Chemother 2012; 67 (8) 1865-1869
  CrossrefPubMedGoogle Scholar
• 47 Lolans K, Calvert K, Won S, Clark J, Hayden MK. Direct ertapenem disk screening method for identification of KPC-producing Klebsiella pneumoniae and Escherichia coli in surveillance swab specimens. J Clin Microbiol 2010; 48 (3) 836-841
  CrossrefPubMedGoogle Scholar
• 48 Adler A, Navon-Venezia S, Moran-Gilad J, Marcos E, Schwartz D, Carmeli Y. Laboratory and clinical evaluation of screening agar plates for detection of carbapenem-resistant Enterobacteriaceae from surveillance rectal swabs. J Clin Microbiol 2011; 49 (6) 2239-2242
  CrossrefPubMedGoogle Scholar
• 49 Landman D, Salvani JK, Bratu S, Quale J. Evaluation of techniques for detection of carbapenem-resistant Klebsiella pneumoniae in stool surveillance cultures. J Clin Microbiol 2005; 43 (11) 5639-5641
  CrossrefPubMedGoogle Scholar
• 50 Vasoo S, Cunningham SA, Kohner PC , et al. Rapid and direct real-time detection of bla _KPC and bla _NDM from surveillance samples. J Clin Microbiol 2013; 51 (11) 3609-3615
  CrossrefPubMedGoogle Scholar
• 51 Bergen PJ, Landersdorfer CB, Zhang J , et al. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?. Diagn Microbiol Infect Dis 2012; 74 (3) 213-223
  CrossrefPubMedGoogle Scholar
• 52 Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 2013; 57 (9) 1300-1303
  CrossrefPubMedGoogle Scholar
• 53 Garonzik SM, Li J, Thamlikitkul V , et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55 (7) 3284-3294
  CrossrefPubMedGoogle Scholar
• 54 Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil AC. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012; 54 (5) 670-680
  CrossrefPubMedGoogle Scholar
• 55 Mohamed AF, Karaiskos I, Plachouras D , et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 2012; 56 (8) 4241-4249
  CrossrefPubMedGoogle Scholar
• 56 Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004; 53 (5) 837-840
  CrossrefPubMedGoogle Scholar
• 57 Plachouras D, Karvanen M, Friberg LE , et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53 (8) 3430-3436
  CrossrefPubMedGoogle Scholar
• 58 Imberti R, Cusato M, Villani P , et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest 2010; 138 (6) 1333-1339
  CrossrefPubMedGoogle Scholar
• 59 Kwa AL, Lim TP, Low JG , et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis 2008; 60 (2) 163-167
  CrossrefPubMedGoogle Scholar
• 60 Mammina C, Bonura C, Di Bernardo F , et al. Ongoing spread of colistin-resistant Klebsiella pneumoniae in different wards of an acute general hospital, Italy, June to December 2011. Euro Surveill 2012; 17 (33) 20248
  PubMedGoogle Scholar
• 61 Bogdanovich T, Adams-Haduch JM, Tian GB , et al. Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258. Clin Infect Dis 2011; 53 (4) 373-376
  CrossrefPubMedGoogle Scholar
• 62 Mezzatesta ML, Gona F, Caio C , et al. Outbreak of KPC-3-producing, and colistin-resistant, Klebsiella pneumoniae infections in two Sicilian hospitals. Clin Microbiol Infect 2011; 17 (9) 1444-1447
  CrossrefPubMedGoogle Scholar
• 63 Al-Agamy MH, Shibl AM, Elkhizzi NA, Meunier D, Turton JF, Livermore DM. Persistence of Klebsiella pneumoniae clones with OXA-48 or NDM carbapenemases causing bacteraemias in a Riyadh hospital. Diagn Microbiol Infect Dis 2013; 76 (2) 214-216
  CrossrefPubMedGoogle Scholar
• 64 Arpin C, Noury P, Boraud D , et al. NDM-1-producing Klebsiella pneumoniae resistant to colistin in a French community patient without history of foreign travel. Antimicrob Agents Chemother 2012; 56 (6) 3432-3434
  CrossrefPubMedGoogle Scholar
• 65 van Duin D, Perez F, Rudin SD , et al. Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother 2014; 58 (7) 4035-4041
  CrossrefPubMedGoogle Scholar
• 66 van Duin D, Cober ED, Richter SS , et al. Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance. Clin Microbiol Infect 2014; 20 (12) O1117-O1120
  CrossrefPubMedGoogle Scholar
• 67 Barbour A, Schmidt S, Ma B , et al. Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet 2009; 48 (9) 575-584
  CrossrefPubMedGoogle Scholar
• 68 Freire AT, Melnyk V, Kim MJ , et al; 311 Study Group. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68 (2) 140-151
  CrossrefPubMedGoogle Scholar
• 69 Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013; 57 (4) 1756-1762
  CrossrefPubMedGoogle Scholar
• 70 Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012; 25 (4) 682-707
  CrossrefPubMedGoogle Scholar
• 71 Clancy CJ, Chen L, Hong JH , et al. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother 2013; 57 (11) 5258-5265
  CrossrefPubMedGoogle Scholar
• 72 Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae . Antimicrob Agents Chemother 2011; 55 (6) 3002-3004
  CrossrefPubMedGoogle Scholar
• 73 Giamarellou H, Galani L, Baziaka F, Karaiskos I. Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae . Antimicrob Agents Chemother 2013; 57 (5) 2388-2390
  CrossrefPubMedGoogle Scholar
• 74 Naparstek L, Carmeli Y, Navon-Venezia S, Banin E. Biofilm formation and susceptibility to gentamicin and colistin of extremely drug-resistant KPC-producing Klebsiella pneumoniae . J Antimicrob Chemother 2014; 69 (4) 1027-1034
  CrossrefPubMedGoogle Scholar
• 75 Clancy CJ, Hao B, Shields RK , et al. Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes. Antimicrob Agents Chemother 2014; 58 (6) 3521-3525
  CrossrefPubMedGoogle Scholar
• 76 Michail G, Labrou M, Pitiriga V , et al. Activity of tigecycline in combination with colistin, meropenem, rifampin, or gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother 2013; 57 (12) 6028-6033
  CrossrefPubMedGoogle Scholar
• 77 Kontopidou F, Giamarellou H, Katerelos P , et al; Group for the Study of KPC-producing Klebsiella pneumoniae infections in intensive care units. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect 2014; 20 (2) O117-O123
  CrossrefPubMedGoogle Scholar
• 78 Livermore DM, Mushtaq S, Warner M , et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 2011; 66 (1) 48-53
  CrossrefPubMedGoogle Scholar
• 79 Parker S, Lipman J, Koulenti D, Dimopoulos G, Roberts JA. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int J Antimicrob Agents 2013; 42 (4) 289-293
  CrossrefPubMedGoogle Scholar
• 80 Dinh A, Salomon J, Bru JP, Bernard L. Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria. Scand J Infect Dis 2012; 44 (3) 182-189
  CrossrefPubMedGoogle Scholar
• 81 Endimiani A, Patel G, Hujer KM , et al. In vitro activity of fosfomycin against bla _KPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother 2010; 54 (1) 526-529
  CrossrefPubMedGoogle Scholar
• 82 Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011; 37 (5) 415-419
  CrossrefPubMedGoogle Scholar
• 83 Pontikis K, Karaiskos I, Bastani S , et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 2014; 43 (1) 52-59
  CrossrefPubMedGoogle Scholar
• 84 Tängdén T, Hickman RA, Forsberg P, Lagerbäck P, Giske CG, Cars O. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother 2014; 58 (3) 1757-1762
  CrossrefPubMedGoogle Scholar
• 85 Whelton A, Nightingale SD, Carter GG, Gordon LS, Bryant HH, Walker WG. Pharmacokinetic characteristics of doxycycline accumulation in normal and severely diseased kidneys. J Infect Dis 1975; 132 (4) 467-471
  CrossrefPubMedGoogle Scholar
• 86 Qureshi ZA, Syed A, Clarke LG, Doi Y, Shields RK. Epidemiology and clinical outcomes of patients with carbapenem-resistant Klebsiella pneumoniae bacteriuria. Antimicrob Agents Chemother 2014; 58 (6) 3100-3104
  CrossrefPubMedGoogle Scholar
• 87 Alexander BT, Marschall J, Tibbetts RJ, Neuner EA, Dunne Jr WM, Ritchie DJ. Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort. Clin Ther 2012; 34 (6) 1314-1323
  CrossrefPubMedGoogle Scholar
• 88 Bratu S, Tolaney P, Karumudi U , et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005; 56 (1) 128-132
  CrossrefPubMedGoogle Scholar
• 89 Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother 2014; [Epub ahead of print]
  PubMedGoogle Scholar
• 90 Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother 2014; 58 (2) 833-838
  CrossrefPubMedGoogle Scholar
• 91 Wang X, Zhang F, Zhao C , et al. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother 2014; 58 (3) 1774-1778
  CrossrefPubMedGoogle Scholar
• 92 Li H, Estabrook M, Jacoby GA, Nichols WW, Testa RT, Bush K. In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother 2014; [Epub ahead of print]
  PubMedGoogle Scholar
• 93 Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). J Antimicrob Chemother 2014; 69 (10) 2713-2722
  CrossrefPubMedGoogle Scholar
• 94 Almaghrabi R, Clancy CJ, Doi Y , et al. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother 2014; 58 (8) 4443-4451
  CrossrefPubMedGoogle Scholar
• 95 O'Hara JA, McGann P, Snesrud EC , et al. Novel 16S rRNA methyltransferase RmtH produced by Klebsiella pneumoniae associated with war-related trauma. Antimicrob Agents Chemother 2013; 57 (5) 2413-2416
  CrossrefPubMedGoogle Scholar
• 96 Zarkotou O, Pournaras S, Tselioti P , et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011; 17 (12) 1798-1803
  CrossrefPubMedGoogle Scholar
• 97 Qureshi ZA, Paterson DL, Potoski BA , et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56 (4) 2108-2113
  CrossrefPubMedGoogle Scholar
• 98 Tumbarello M, Viale P, Viscoli C , et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55 (7) 943-950
  CrossrefPubMedGoogle Scholar
• 99 Daikos GL, Tsaousi S, Tzouvelekis LS , et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58 (4) 2322-2328
  CrossrefPubMedGoogle Scholar
• 100 Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2014; 20 (9) 862-872
  CrossrefPubMedGoogle Scholar